Nuclear Medicine Therapy

Liver malignancy, be it primary tumors like Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma, is one of the top five most common cancers worldwide and is also a frequent cause of cancer-related mortality. In most of the cases, Hepatocellular Carcinoma (HCC) is often diagnosed late in the intermediate-advanced stage (stage B and C). Because of this often-late diagnosis, radical therapy doesn’t offer much success. While a few curative and/ or palliative therapies might help, but they are not often characterized by a favorable safety or efficacy ratio. Hence for this intermediate to advanced stages of HCC, internal radionuclide therapy is emerging as a good therapeutic option. And according to several studies, Transarterial Radioembolization (TARE) or intra-arterial injection of a radiolabeled embolising agent has led to extremely promising results, both in terms of demonstration of a good tolerability profile and disease control. Transarterial Radioembolization (TARE) is also sim...

  The incidence of Hepatocellular Carcinoma or HCC has been increasing over the past several years and several studies have projected that the incidence of HCC will continue to rise in the coming years. Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC. However, as the experience of  Transarterial Radioembolisation or TARE  has evolved, it is playing an increasingly important role in the treatment of unrespectable HCC. Studies and trials have shown that TARE has many potential advantages over TACE and there is now substantial evidence to favor TARE over TACE. The many potential advantages of TARE when compared with TACE are as below: · Several studies have shown a statistically significant overall survival advantage with TARE as compared to TACE. · TARE has better health-relat...